2019
DOI: 10.1016/j.bbmt.2018.12.602
|View full text |Cite
|
Sign up to set email alerts
|

Use of the Quantitative Karius® Plasma Next Generation Sequencing Cell-Free Pathogen DNA Test to Detect and Monitor Cytomegalovirus Infection in Allogeneic Stem-Cell Transplant Recipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Identifying optimal utilization, both clinical indications and timing, of the plasma mcfDNA sequencing in future studies to augment clinical decision-making and integration into current testing algorithms ( 17 , 18 , 33 35 ) will serve to improve the utility of the test. Examples of such studies include two recently completed prospective, observational clinical trials of the use of the Karius Test to diagnose pneumonia in immunocompromised patients (NCT04047719) ( 36 ) and infections in stem cell transplant inpatients and outpatients over time (NCT02804464) ( 26 ), respectively.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Identifying optimal utilization, both clinical indications and timing, of the plasma mcfDNA sequencing in future studies to augment clinical decision-making and integration into current testing algorithms ( 17 , 18 , 33 35 ) will serve to improve the utility of the test. Examples of such studies include two recently completed prospective, observational clinical trials of the use of the Karius Test to diagnose pneumonia in immunocompromised patients (NCT04047719) ( 36 ) and infections in stem cell transplant inpatients and outpatients over time (NCT02804464) ( 26 ), respectively.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, infectious disease and hematology/oncology providers comprised most (78%) of the ordering clinicians, aligning with expectations that these clinicians commonly care for critically ill and IC patients with difficult-to-diagnose infections. Constraints of the underlying data structure prevented analyzing the data from the 12% of patients who had repeated testing to determine whether these tests were performed serially to diagnose new suspected infections or to monitor therapy response or conduct pathogen surveillance among immunocompromised patients as described by others ( 8 , 26 , 64 66 ). Further, the underlying data structure limited our ability to stratify the results by improvements to the bioinformatics pipeline over the course of the study period.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation